Comparar compuestos
Seleccione hasta 3 compuestos para comparar protocolos, mecanismos, criterios de valoración y hallazgos de seguridad en paralelo.
Peptijournal · Cagrilintide vs Tirzepatide · https://peptijournal.com/compare?c=cagrilintide,tirzepatide · Impreso
01Protocol
Cagrilintide
- Viales
- 5 mg
- Datos de dosis
- Referencia de laboratorio; no indicado
Tirzepatide
- Start
- 2.5 mg
- Range
- 2.5–15 mg
- Frequency
- Once weekly
- Cycle
- Ongoing, titrated every 4 weeks
- Vials
- 10 / 15 / 30 mg
- Ajuste gradual
- Weeks 1–4: 2.5 mg
- Weeks 5–8: 5 mg
- Weeks 9–12: 7.5 mg
- Weeks 13–16: 10 mg
- Weeks 17–20: 12.5 mg
- Weeks 21+: 15 mg (max studied)
02Quick calculator
Cagrilintide
Tirzepatide
03Mechanism of action
Cagrilintide
Cagrilintide is a long-acting analogue of amylin, a pancreatic hormone that induces satiety. It is studied alone and combined with semaglutide (CagriSema).
Tirzepatide
Tirzepatide is a single peptide that activates both the GIP and GLP-1 receptors (a 'twincretin'). It carries a fatty-acid chain for albumin binding and once-weekly exposure. Combined GIP/GLP-1 signalling affects insulin and glucagon secretion, gastric emptying and appetite.
04Study endpoints
Cagrilintide
- Phase 2 (26 weeks): every cagrilintide arm reduced weight more than placebo (6.0%–10.8% vs 3.0%); the top arm also beat liraglutide (10.8% vs 9.0%).
- Combination evidence, not cagrilintide-alone efficacy: REDEFINE 1 (3,417 adults without diabetes) reported −20.4% mean weight change with cagrilintide–semaglutide vs −3.0% with placebo at 68 weeks using the treatment-policy estimand.
- Combination evidence in type 2 diabetes: REDEFINE 2 reported −13.7% mean weight change with cagrilintide–semaglutide vs −3.4% with placebo at 68 weeks, not a standalone cagrilintide result.
Tirzepatide
- SURMOUNT-1 (obesity, no diabetes): mean weight change of −15.0% to −20.9% across dose arms vs −3.1% with placebo at week 72.
- SURPASS-2 (type 2 diabetes): every tirzepatide arm lowered HbA1c more than semaglutide (−2.01 to −2.30 vs −1.86 points).
- SURMOUNT-5 (head-to-head, obesity): −20.2% weight change vs −13.7% with semaglutide at week 72.
05Safety & regulatory findings
Cagrilintide
- Investigational: not approved as a standalone medicine.
- Phase 2: gastrointestinal events in 41%–63% vs 32% on placebo, mainly nausea. REDEFINE 1 combination arm: gastrointestinal events in 79.6% vs 39.9% with placebo.
Tirzepatide
- FDA-approved (as Mounjaro and Zepbound) for specific indications; research-grade material is not an approved product.
- Gastrointestinal events were the most common adverse effects and occurred mostly during dose escalation.